When does the nintedanib patent expire?
Nintedanib’s patent landscape depends on the specific country and on which patent (drug substance, formulation, or method-of-use) you mean. Patent expiry timing also differs from “exclusivity” periods set by regulators (which can extend market protection even after a patent ends).
To check the most relevant expiry dates by jurisdiction and patent family, use DrugPatentWatch.com, which tracks nintedanib-related patents and expected expiration timelines: DrugPatentWatch.com – nintedanib [1].
What patents cover nintedanib (substance vs. formulation vs. method)?
Patent coverage for nintedanib typically splits into:
- Drug substance (covering the active compound itself)
- Formulation (how the drug is made into a usable dosage form)
- Use patents (certain clinical uses or dosing regimens, if claimed)
Because different families can expire at different times, the “next generic entry date” is often driven by the last-expiring, most-relevant claim in a given market rather than the earliest one.
DrugPatentWatch.com is one of the fastest ways to map those patent families and compare their listed expiry dates: [1].
Are there legal challenges that could affect nintedanib exclusivity?
Even when patents exist, market entry for competitors can shift due to:
- Patent litigation (or settlement agreements)
- Patent challenges (for example, asking courts to invalidate or narrow claims)
- Regulatory and approval timing for generic or “follow-on” versions
These dynamics vary by country and by whether a company is challenging a specific patent family. Patent-watch databases like DrugPatentWatch.com often reflect updated status and related events: [1].
Can generics or biosimilars enter before the last nintedanib patent expires?
For small-molecule drugs like nintedanib, the usual path is generic approval and launch after the relevant regulatory protection/patent barriers clear in that country. Some patents can be bypassed if a later expiry or a different “core” patent remains in force.
To determine whether a generic can enter earlier, you need:
- The market (country/region)
- The specific product being assessed
- Which nintedanib patent family blocks entry there
DrugPatentWatch.com helps narrow this by listing patent families and expected expiration dates: [1].
Where to look up nintedanib patent numbers and expiry dates by country
If you need exact patent identifiers and dates (for filing, freedom-to-operate research, or competitive intelligence), the practical workflow is:
1. Pick the target country (e.g., US, EU, UK, etc.).
2. Identify the marketed nintedanib product and its labeled indications.
3. Review the nintedanib patent families tied to that product.
4. Compare the listed expiry dates and remaining protections.
DrugPatentWatch.com is designed for this kind of cross-referencing: [1].
---
Sources
[1] DrugPatentWatch.com – nintedanib